论文部分内容阅读
目的:探讨肿瘤-睾丸抗原(CTA)MAGE-1和NY-ESO-1作为胃肠间质瘤(GISTs)免疫治疗特异性靶点及MAGE-1和NY-ESO-1mRNA作为辅助GISTs危险度分级指标的可能性,及其与GISTs生物学行为的关系.方法:采用逆转录-聚合酶链反应(RT-PCR)技术,检测30例GISTs中MAGE-1和NY-ESO-1m R NA的表达,并取正常胃肠道组织作为阴性对照组,同时分析MAGE-1和NY-ESO-1mRNA表达与病理特征的关系.结果:正常对照组中无阳性表达,30例GISTs中,18例至少表达一种CTA,MAGE-1和NY-E S O-1m R NA在G I S T s中的表达率分别为30%和47%.MAGE-1和NY-ESO-1mRNA表达与患者年龄、性别和病理类型无关,而与肿瘤生长部位、肿瘤大小及危险度分级有关(P<0.05).MAGE-1和NY-ESO-1mRNA在低危、中危、高危三个组中表达量随着危险度分级的升高而增高,三组间差异有统计学意义(P<0.05).MAGE-1和NY-ESO-1mRNA在GISTs中的表达不存在相关性(r=0.018,P>0.05).结论:MAGE-1和NY-ESO-1mRNA在GISTs中的高特异性表达,其抗原有望成为GISTs免疫治疗特异性的靶点;MAGE-1和NY-ESO-1mRNA表达与GISTs危险度分级有关,MAGE-1和NY-ESO-1mRNA有望成为辅助GISTs危险度分级的诊断指标.
Objective: To investigate the immunotherapy target of MAGE-1 and NY-ESO-1 of tumor-testis antigen (CTA) as gastrointestinal stromal tumors (GISTs) and MAGE-1 and NY-ESO- And the relationship with the biological behavior of GISTs.Methods: The expression of MAGE-1 and NY-ESO-1m RAN in 30 cases of GISTs were detected by reverse transcription-polymerase chain reaction (RT-PCR) , And normal gastrointestinal tissue was taken as a negative control group.Meanwhile, the relationship between the expression of MAGE-1 and NY-ESO-1 mRNA and the pathological features was analyzed.Results: Of the 30 GISTs, 18 of them were at least expressed The expression rates of CTA, MAGE-1 and NY-ESO-1m RNA in GISTs were 30% and 47%, respectively.The expression of MAGE-1 and NY-ESO-1 mRNA correlated with age, sex and pathological type (P <0.05) .MAGE-1 and NY-ESO-1mRNA levels in the low, medium and high risk groups were graded according to the degree of risk (P <0.05) .No correlation was found between the expression of MAGE-1 and NY-ESO-1mRNA in GISTs (r = 0.018, P> 0.05) .Conclusion: -1 and NY-ESO-1 mRNA at GISTs, and their antigens are expected to be the specific targets of immunotherapy for GISTs. The expression of MAGE-1 and NY-ESO-1mRNA is related to the risk of GISTs, and MAGE-1 and NY-ESO-1mRNA are expected to be complementary Diagnostic index of GISTs risk grade.